Mark Zobeck, Javed Khan, Rajkumar Venkatramani, M. Fatih Okcu, Michael E. Scheurer, Philip J. Lupo
{"title":"利用体细胞分子生物标记物改善横纹肌肉瘤的个体化预后预测","authors":"Mark Zobeck, Javed Khan, Rajkumar Venkatramani, M. Fatih Okcu, Michael E. Scheurer, Philip J. Lupo","doi":"10.1101/2024.09.04.24313032","DOIUrl":null,"url":null,"abstract":"<strong>Purpose</strong> Molecular markers, such as <em>FOXO1</em> fusion genes and <em>TP53</em> and <em>MYOD1</em> mutations, increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce individualized prognosis predictions that can further improve treatment selection.","PeriodicalId":501437,"journal":{"name":"medRxiv - Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers\",\"authors\":\"Mark Zobeck, Javed Khan, Rajkumar Venkatramani, M. Fatih Okcu, Michael E. Scheurer, Philip J. Lupo\",\"doi\":\"10.1101/2024.09.04.24313032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Purpose</strong> Molecular markers, such as <em>FOXO1</em> fusion genes and <em>TP53</em> and <em>MYOD1</em> mutations, increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce individualized prognosis predictions that can further improve treatment selection.\",\"PeriodicalId\":501437,\"journal\":{\"name\":\"medRxiv - Oncology\",\"volume\":\"40 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.04.24313032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.04.24313032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers
Purpose Molecular markers, such as FOXO1 fusion genes and TP53 and MYOD1 mutations, increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce individualized prognosis predictions that can further improve treatment selection.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
